MARKET

ACRS

ACRS

Aclaris
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.90
-1.26
-6.94%
After Hours: 16.90 0 0.00% 16:44 09/20 EDT
OPEN
17.53
PREV CLOSE
18.16
HIGH
18.09
LOW
16.61
VOLUME
632.41K
TURNOVER
--
52 WEEK HIGH
30.38
52 WEEK LOW
2.250
MARKET CAP
1.03B
P/E (TTM)
-11.5068
1D
5D
1M
3M
1Y
5Y
Looking into Aclaris Therapeutics's Return on Capital Employed
After pulling data from Benzinga Pro it seems like during Q2, Aclaris Therapeutics's (NASDAQ:ACRS) reported sales totaled $1.82 million. Despite a 36.89% in earnings, the company posted a loss of $18.01 million.
Benzinga · 08/27 21:13
Aclaris Therapeutics Announces Proposed Settlement And Settlement Hearing Of Stockholder Derivative Action
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that a settlement hearing (the
Benzinga · 08/27 20:01
Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that a settlement hearing (the "Settlement Hearing") will be held on Novembe...
GlobeNewswire · 08/27 20:01
Aclaris Therapeutics Says Settlement Hearing of Derivatives Suit Due Nov. 30
MT Newswires · 08/27 16:39
Aclaris Therapeutics to Participate in Upcoming Investor Conferences
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in the following upcoming investor conferen...
GlobeNewswire · 08/26 20:01
The 9.4% return this week takes Aclaris Therapeutics' (NASDAQ:ACRS) shareholders one-year gains to 510%
Some Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ) shareholders are probably rather concerned to see the share price fall...
Simply Wall St. · 08/25 10:16
Commodore Capital Lp Buys Celcuity Inc, C4 Therapeutics Inc, Cytokinetics Inc, Sells , Trillium ...
GuruFocus News · 08/23 21:38
Perceptive Advisors Llc Buys Nautilus Biotechnology Inc, Singular Genomics Systems Inc, United ...
GuruFocus News · 08/19 13:38
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACRS. Analyze the recent business situations of Aclaris through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACRS stock price target is 34.80 with a high estimate of 50.00 and a low estimate of 26.00.
EPS
Institutional Holdings
Institutions: 165
Institutional Holdings: 64.01M
% Owned: 104.56%
Shares Outstanding: 61.22M
TypeInstitutionsShares
Increased
34
13.09M
New
48
4.76M
Decreased
32
5.85M
Sold Out
18
1.44M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.58%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Non-Executive Chairman/Independent Director
Christopher Molineaux
President/Chief Executive Officer/Co-Founder/Director
Neal Walker
Chief Financial Officer
Frank Ruffo
Other
Kamil Ali-Jackson
Other
David Gordon
Independent Director
Maxine Gowen
Independent Director
William Humphries
Independent Director
Anand Mehra
Independent Director
Vincent Milano
Independent Director
Andrew Powell
Independent Director
Bryan Reasons
Independent Director
Andrew Schiff
No Data
About ACRS
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drug candidates for immuno-inflammatory diseases. Its drug candidates include ATI-450, ATI-1777, ATI-2138 and Undisclosed- Gut Restricted Program. Its ATI-450 is an investigational oral, small molecule selective mitogen-activated protein kinase-activated protein kinase 2, or MK2, inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777 is an investigational topical soft-JAK inhibitor compound, for the treatment of atopic dermatitis. Its ATI-2138 is an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, as al treatment for psoriasis and/or inflammatory bowel disease, which are both T-cell mediated autoimmune diseases.

Webull offers kinds of Aclaris Therapeutics Inc stock information, including NASDAQ:ACRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACRS stock methods without spending real money on the virtual paper trading platform.